Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term Prospects [Seeking Alpha]

Jounce Therapeutics, Inc. (JNCE) 
Last jounce therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com
Company Research Source: Seeking Alpha
Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term Prospects Summary Jounce Therapeutics established updated deal with Celgene with the potential to earn up to $530 million in payments based on JTX-8064. Vopratelimab plus ipilimumab has seen positive synergistic effects in the phase 1/2 ICONIC study in solid tumor patients. Based on positive data from the phase 1/2 ICONIC study, Jounce moved forward to initiate its phase 2 EMERGE study exploring vopratelimab plus ipilimumab in NSCLC or urothelial cancer. Jounce Therapeutics had $173.2 million in cash, cash equivalents and investments as of March 31, 2019; Updated deal with Celgene brings in $50 million which means no risk of near-term dilution. JNCE established an updated deal with its partner CELG Updated Deal Is Still Solid The newly updated deal allows Celgene to gain access to a macrophage drug known as JTX-8064. This deal involves Jounce receiving an upfront payment of $50 million, with the potential to earn $480 Show less Read more
Impact Snapshot
Event Time:
JNCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for JNCE alerts
Opt-in for
JNCE alerts

from News Quantified
Opt-in for
JNCE alerts

from News Quantified